Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenJared M. Baeten, Connie Celum, Carey Farquhar et al.|New England Journal of Medicine|2012Cited by 3.3k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Deborah Donnell et al.|New England Journal of Medicine|2021Cited by 847
HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV PreventionDeborah Donnell, Connie Celum, Jared M. Baeten et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2014Cited by 364
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J. Landovitz, Joseph J. Eron, Sue Li et al.|PLoS Medicine|2018Cited by 171
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J. Landovitz, Craig W. Hendrix, Sue Li et al.|The Lancet HIV|2020Cited by 171